Alexander's, Inc. (NYSE:ALX)

Alexander's, Inc. ALX

Real Estate - REIT - Retail - NYSE - US

Watchlist

$ 208.65

-1.15 %

$ 1.07 B

Market Cap

24.66

P/E

1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one ALX stock under the worst case scenario is HIDDEN Compared to the current market price of 209 USD, Alexander's, Inc. is HIDDEN

ALX Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one ALX stock under the base case scenario is HIDDEN Compared to the current market price of 209 USD, Alexander's, Inc. is HIDDEN

ALX Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one ALX stock under the best case scenario is HIDDEN Compared to the current market price of 209 USD, Alexander's, Inc. is HIDDEN

ALX Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart ALX

FINANCIALS

Annual
Quarterly

54.1 M OPERATING CASH FLOW

-13.2 M INVESTING CASH FLOW

-200 M FINANCING CASH FLOW

30.8 M OPERATING CASH FLOW

-9.95 M INVESTING CASH FLOW

-24.2 M FINANCING CASH FLOW

Balance Sheet Alexander's, Inc.

1.34 B ASSETS
1.16 B LIABILITIES

Current Assets	511 M
Cash & Short-Term Investments	339 M
Receivables	117 M
Other Current Assets	55.3 M
Non-Current Assets	831 M
Long-Term Investments	0
PP&E	0
Other Non-Current Assets	831 M

Current Liabilities	39.9 M
Accounts Payable	38.7 M
Short-Term Debt	0
Other Current Liabilities	1.16 M
Non-Current Liabilities	1.12 B
Long-Term Debt	1.1 B
Other Non-Current Liabilities	21.4 M

EFFICIENCY

Earnings Waterfall Alexander's, Inc.

Revenue	226 M
Cost Of Revenue	0
Gross Profit	226 M
Operating Expenses	226 M
Operating Income	0
Other Expenses	-43.4 M
Net Income	43.4 M

RATIOS

0.00% OPERATING MARGIN

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Alexander's, Inc.

Net Income	43.4 M
Depreciation & Amortization	37.9 M
Capital Expenditures	0
Stock-Based Compensation	450 K
Change in Working Capital	-47.8 M
Others	-14 M
Free Cash Flow	54.1 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Alexander's, Inc.

Wall Street analysts predict an average 1-year price target for ALX of $135 , with forecasts ranging from a low of $125 to a high of $145 .

ALX Lowest Price Target Wall Street Target

125 USD -40.09%

ALX Average Price Target Wall Street Target

135 USD -35.30%

ALX Highest Price Target Wall Street Target

145 USD -30.51%

4. DIVIDEND ANALYSIS

2.25% DIVIDEND YIELD

4.5 USD DIVIDEND PER SHARE

5. COMPETITION

Saul Centers, Inc. is a self-managed, self-administered equity REIT headquartered in Bethesda, Maryland, which currently operates and manages a real estate portfolio of 60 properties which includes (a) 50 community and neighborhood shopping centers and seven mixed-use properties with approximately 9.8 million square feet of leasable area and (b) three land and development properties.

124 USD

BFS

Undervalued 243.18%

Acadia Realty Trust is an equity real estate investment trust focused on delivering long-term, profitable growth via its dual Core Portfolio and Fund operating platforms and its disciplined, location-driven investment strategy.

20.7 USD

AKR

Overvalued 1.32%

InvenTrust Properties Corp. is a premier multi-tenant retail REIT that owns, leases, redevelops, acquires and manages grocery-anchored neighborhood centers, and select power centers that often have a grocery component, predominantly in Sun Belt markets with favorable demographics.

6. Ownership

Insider Ownership Alexander's, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
10 years ago Jun 02, 2014	Bought 6.15 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	+ 17	361.5 USD
10 years ago Jun 04, 2014	Bought 5.42 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	+ 15	361.5 USD
10 years ago Jun 10, 2014	Bought 96.9 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	+ 268	361.5 USD
10 years ago Jun 11, 2014	Bought 3.24 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	+ 9	360.5 USD
10 years ago Jun 12, 2014	Bought 2.52 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	+ 7	360.5 USD
10 years ago Oct 02, 2014	Bought 3.34 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	+ 9	371 USD
10 years ago Oct 06, 2014	Bought 6.31 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	+ 17	371 USD
10 years ago Oct 07, 2014	Bought 2.6 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	+ 7	371 USD
10 years ago Oct 08, 2014	Bought 2.23 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	+ 6	371 USD
16 years ago Aug 04, 2008	Sell 184 K USD	WIGHT RUSSELL B JR director, 10 percent owner:	- 500	367.51 USD

7. News

Is Alexander's (ALX) Outperforming Other Finance Stocks This Year? Here is how Alexander's (ALX) and Banco Bilbao (BBVA) have performed compared to their sector so far this year. zacks.com - 2 weeks ago

Best Income Stocks to Buy for March 13th ALX, HAFC and FHB made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 13, 2025. zacks.com - 3 weeks ago

Best Income Stocks to Buy for March 11th ALX, VLY and HAFC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 11, 2025. zacks.com - 3 weeks ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI globenewswire.com - 1 month ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast featuring company leadership and external key opinion leaders to take place today at 6:00 a.m. PT/9:00 a.m. globenewswire.com - 1 month ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open. globenewswire.com - 1 month ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. globenewswire.com - 1 month ago

Inflation Isn't Dead Yet US equity markets flirted with fresh record-highs this week while benchmark interest rates hovered around two-month lows as investors weighed positive earnings news against uncomfortable hot inflation data. Complicating the policy outlook for the Federal Reserve, CPI data showed the fastest monthly rise in consumer prices since August, prompting a pledge from Powell for "more work to do." Snapping a two-week losing streak, the S&P 500 rebounded by 1.5%, closing fractionally below its prior record-high set in late January. The tech-heavy Nasdaq 100 rallied nearly 3%. seekingalpha.com - 1 month ago

Alexander's (ALX) Q4 FFO and Revenues Surpass Estimates Alexander's (ALX) came out with quarterly funds from operations (FFO) of $4.06 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to FFO of $4.99 per share a year ago. zacks.com - 1 month ago

Alexander's Announces Fourth Quarter Financial Results PARAMUS, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-K for the year ended December 31, 2024 today and reported: globenewswire.com - 1 month ago

Alexander's Declares Quarterly $4.50 Dividend on Common Shares PARAMUS, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on February 28, 2025 to stockholders of record on February 18, 2025. globenewswire.com - 1 month ago

Alexander's: Bloomberg Lease Secured, Is The Dividend Safe Alexander's has dipped materially from its 52-week high following a spike in the US 10-year Treasury yield. The REIT generated fiscal 2024 third-quarter FFO of $2.84 per share, down from its year-ago comp. A $354.8 million cash and cash equivalents position helps to provide a buffer for the REIT, but 2025 debt maturities are heavy and will pose a challenge. seekingalpha.com - 2 months ago

8. Profile Summary

Alexander's, Inc. ALX

COUNTRY US

INDUSTRY REIT - Retail

MARKET CAP $ 1.07 B

Dividend Yield 2.25%

Description Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.

Contact 210 Route 4 East, Paramus, NJ, 07652 https://www.alx-inc.com

IPO Date Feb. 21, 1973

Employees 90

Officers Mr. Steven J. Borenstein Secretary Mr. Gary W. Hansen Chief Financial Officer Mr. Steven Roth Chairman of the Board & Chief Executive Officer

Price Chart ALX

Alexander's, Inc. ALX

Free

Unlimited Plan

Premium Plan